ClinicalTrials.gg
Not yet recruitingNCT05659953Updated Sep 1, 2026

LMT503 First-in-human SAD, MAD, and FE Study

A Phase 1 interventional study of LMT503 and Placebo in Inflammatory Bowel Disease, Colitis, Ulcerative and Crohn Disease, sponsored by Lmito Therapeutics Inc.. Not yet recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Lmito Therapeutics Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Inflammatory Bowel Diseases with a site in Netherlands — 22 open to participants now, 28 under way, 7 of them phase 3. Inflammatory Bowel Diseases · Netherlands.

Planned enrollment
37th of 61
72 · median 120
Started
2027
the only one that year
Phase 1
Only one
of the 79
Primary completion
2027-09
later than 20 of 27 live
Registered
59th of 79
by date

Among the 79 studies in Inflammatory Bowel Diseases with a site in Netherlands, this one is the 37th largest by planned enrollment of the 61 interventional ones that give a count, is the only one that started in 2027, is the only one in phase 1, reaches primary completion later than 20 of the 27 other live ones, and was the 59th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

22 of the 79 studies in Inflammatory Bowel Diseases with a site in Netherlands are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Inflammatory Bowel Diseases with a site in Netherlands, or all of them as a file.
02

Study summary

This is a double-blind, randomized, placebo-controlled study, consisting of a single ascending dose (SAD) part with integrated food effect (FE) arm, and a multiple ascending dose (MAD) part to assess the safety, tolerability, and PK of ascending single and multiple oral doses of LMT503. The study will start with the SAD part.

03

Conditions studied

  • Inflammatory Bowel Disease
  • Colitis, Ulcerative
  • Crohn Disease

Keywords

  • Macrophage Polarization
  • Cell metabolism modulation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age : 18 to 65 years, inclusive, at screening
  • Weight : 50 to 110 kg, inclusive, at screening
  • : 18.0 to 30.0 kg/m2, inclusive, at screening
  • At screening, females can be of (but not pregnant or lactating), or of nonchildbearing potential (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1 year [amenorrhea duration of 12 consecutive months]); nonpregnancy will be confirmed for all females by a negative serum pregnancy test at screening, (each) admission, and follow-up.
  • Female subjects of childbearing potential who have a fertile male sexual partner must agree to use adequate from at least 4 weeks prior to (first) administration of the study drug until 90 days after the follow up visit. Adequate contraception is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm, a cervical cap, or a condom. Total abstinence from heterosexual intercourse, in accordance with the lifestyle of the subject, is also acceptable.
  • Male subjects, if not surgically sterilized, must agree to use adequate contraception and not donate sperm from (first) admission to the clinical research center until 90 days after the follow-up visit. Adequate contraception for the male subject (and his female partner, if she is of childbearing potential) is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm, a cervical cap, or a condom. Total abstinence from heterosexual intercourse, in accordance with the lifestyle of the subject, is also acceptable.
  • Supine systolic blood pressure between 90 to 140 mmHg, inclusive, diastolic blood pressure between 45 to 90 mmHg, inclusive, and a heart rate between 40 to 100 bpm, inclusive, at screening. If initial results do not meet these criteria, blood pressure may be repeated if in the judgment of the Investigator there is a reason to believe the initial result is inaccurate.
  • All prescribed medication must have been stopped at least 30 days prior to (first) admission to the clinical research center. An exception is made for hormonal contraceptives, which may be used throughout the study.
  • All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (eg, St. John's wort) must have been stopped at least 14 days prior to (first) admission to the clinical research center. An exception is made for paracetamol, which is allowed up to admission to the clinical research center.
  • Ability and willingness to abstain from alcohol from 48 hours (2 days) prior to screening and (first) admission to the clinical research center.
  • Ability and willingness to abstain from methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, energy drinks) and grapefruit (juice) from 48 hours (2 days) prior to (each) admission to the clinical research center.
  • Good physical and mental health on the basis of medical history, physical examination, clinical laboratory, , and vital signs, as judged by the Investigator.
  • Willing and able to sign the ICF.

Exclusion criteria

Exclusion Criteria:

  • Previous participation in the current study.
  • Employee of ICON or the Sponsor.
  • History of relevant drug and/or food allergies.
  • Using tobacco products within 2 months prior to (first) admission.
  • History of alcohol abuse or drug addiction (including soft drugs like cannabis products).
  • Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, gamma hydroxybutyric acid, tricyclic antidepressants, and alcohol) at screening or (at one of the) admission(s) to the clinical research center.
  • Average intake of more than 24 units of alcohol per week: 1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits).
  • Positive screen for surface antigen (HBsAg), virus (HCV) antibodies, or (HIV) 1 and 2 antibodies.
  • Participation in a drug study within 30 days prior to (the first) drug administration in the current study. Participation in 4 or more other drug studies in the 12 months prior to (the first) drug administration in the current study.
  • Donation or loss of more than 450 mL of blood within 60 days prior to (the first) drug administration. Donation or loss of more than 1.5 liters of blood (for male subjects)/more than 1.0 liters of blood (for female subjects) in the 10 months prior to (the first) drug administration in the current study.
  • Significant and/or acute illness within 5 days prior to (the first) drug administration that may impact safety assessments, in the opinion of the Investigator.
  • Unwillingness to consume the FDA breakfast.
  • Unsuitable veins for infusion or blood sampling.
  • Vaccination against SARS-CoV-2 planned between 2 weeks prior to (first) admission and follow-up.
  • Positive nasopharyngeal PCR test for SARS-CoV-2 on Day -1 or if there was any known close contact with a person who tested positive for SARS-CoV-2 or with a COVID-19 patient within 2 weeks prior to admission.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    LMT503

    Subjects receiving LMT503 orally

    Drug: LMT503

  • Placebo comparator
    Placebo

    Subjects receiving Matched Placebo orally

    Drug: Placebo

Interventions

  • DrugLMT503

    Subjects will receive one of several different oral doses of LMT503 once daily

  • DrugPlacebo

    Subjects will receive one of several different oral doses of Placebo once daily

06

What researchers measure

Primary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAEs) in the SAD and MAD part

    Incidence and severity of AEs including clinical significant changes in safety laboratory, vital signs, 12-lead ECG, continuous cardiac monitoring (telemetry), and physical examination

    Time frame: up to Day 17

Secondary outcomes

  1. PK parameter

    Maximum observed concentration (Cmax) of LMT503 in plasma

    Time frame: up to Day 10, 72 hours post dose

  2. PK parameter

    Time to maximum observed concentration (Tmax) of LMT503 in plasma

    Time frame: up to Day 10, 72 hours post dose

  3. PK parameter

    Apparent terminal elimination half-life (t1/2) of LMT503 in plasma

    Time frame: up to Day 10, 72 hours post dose

  4. PK parameter

    Area under the plasma concentration-time curve from time 0 to time tau (AUC0-tau) of LMT503 in plasma

    Time frame: up to Day 10, 72 hours post dose

  5. PK parameter

    Terminal elimination rate constant (kel) of LMT503 in plasma

    Time frame: up to Day 10, 72 hours post dose

  6. PK parameter

    Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) of LMT503 in plasma (SAD and FE part)

    Time frame: up to Day 10, 72 hours post dose

  7. PK parameter

    Area under the plasma concentration-time curve up to time t (AUC0-t) of LMT503 in plasma (SAD and FE part)

    Time frame: up to Day 10, 72 hours post dose

  8. PK parameter

    Concentration at the end of the dosing interval (Ctrough) of LMT503 in plasma (MAD only)

    Time frame: up to Day 10, 72 hours post dose

  9. PK parameter

    Cumulative amount of LMT503 excreted in urine to time t (Aeurine) (SAD and FE part)

    Time frame: up to Day 10, 72 hours post dose

  10. PK parameter

    Cumulative amount of LMT503 excreted in urine to time tau (Aeurine,ss) (MAD only)

    Time frame: up to Day 10, 72 hours post dose

  11. Number of Treatment Emergent Adverse Events (TEAEs) in Food Effect part

    Incidence and severity of AEs including clinical significant changes in safety laboratory, vital signs, 12-lead ECG, continuous cardiac monitoring (telemetry), and physical examination

    Time frame: up to Day 4, 72 hours post dose

07

Study locations

1 site
  • ICON plc Company - Early Development Services
    Groningen, NZ 9728, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Sep 2027, 6 months later.

Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's planned 6 months is below that.

Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2022
First posted
Dec 21, 2022
StartEst.
Mar 1, 2027
Primary completionEst.
Sep 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05659953
Lead sponsor
Lmito Therapeutics Inc.
Responsible party
Sponsor
First posted
Dec 21, 2022
Start date
Mar 1, 2027 (estimated)
Primary completion
Sep 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Maria Velinova, MD, PhD
Contact
info@praclinicaltrials.com
0800-0292044
Wheeseong LEE, PhD
study chair · Lmito Therapeutics Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion